PL2433953T3 - Peptydy o zdolności przenikania przez błonę komórkową - Google Patents

Peptydy o zdolności przenikania przez błonę komórkową

Info

Publication number
PL2433953T3
PL2433953T3 PL10777770T PL10777770T PL2433953T3 PL 2433953 T3 PL2433953 T3 PL 2433953T3 PL 10777770 T PL10777770 T PL 10777770T PL 10777770 T PL10777770 T PL 10777770T PL 2433953 T3 PL2433953 T3 PL 2433953T3
Authority
PL
Poland
Prior art keywords
cell membrane
permeable peptides
peptides
permeable
membrane
Prior art date
Application number
PL10777770T
Other languages
English (en)
Inventor
Mariko Morishita
Kozo Takayama
Reiji Nishio
Nobuo Ida
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of PL2433953T3 publication Critical patent/PL2433953T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Insects & Arthropods (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10777770T 2009-05-20 2010-05-19 Peptydy o zdolności przenikania przez błonę komórkową PL2433953T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2009122096 2009-05-20
JP2010071774 2010-03-26
PCT/JP2010/058420 WO2010134537A1 (ja) 2009-05-20 2010-05-19 細胞膜透過性ペプチド
EP10777770.8A EP2433953B1 (en) 2009-05-20 2010-05-19 Cell membrane-permeable peptides

Publications (1)

Publication Number Publication Date
PL2433953T3 true PL2433953T3 (pl) 2015-12-31

Family

ID=43126214

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10777770T PL2433953T3 (pl) 2009-05-20 2010-05-19 Peptydy o zdolności przenikania przez błonę komórkową

Country Status (13)

Country Link
US (1) US8772449B2 (pl)
EP (1) EP2433953B1 (pl)
JP (1) JP5653214B2 (pl)
KR (1) KR101783291B1 (pl)
CN (1) CN102428096B (pl)
AU (1) AU2010250452B2 (pl)
BR (1) BRPI1008230B1 (pl)
CA (1) CA2762551C (pl)
ES (1) ES2546304T3 (pl)
MX (1) MX2011011960A (pl)
PL (1) PL2433953T3 (pl)
RU (1) RU2548807C2 (pl)
WO (1) WO2010134537A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102580061B (zh) * 2011-12-01 2015-04-22 武汉健宇生物医药科技有限公司 一种鼻用型胰岛素制剂及制备方法
WO2013169060A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 패혈증 예방 또는 치료용 조성물
ES2691070T3 (es) 2012-05-11 2018-11-23 Kael-Gemvax Co.,Ltd Péptidos antiinflamatorios y composición que comprende los mismos
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
US9631184B2 (en) 2012-09-19 2017-04-25 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
TWI616531B (zh) 2012-09-19 2018-03-01 傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物（二）
KR102258864B1 (ko) 2013-04-19 2021-06-01 주식회사 젬백스앤카엘 허혈성 손상 치료 및 예방용 조성물
RU2677277C2 (ru) 2013-06-07 2019-01-16 Джемвакс Энд Каэл Ко., Лтд. Биологические маркеры, которые могут быть использованы в иммунотерапии рака
TWI539960B (zh) 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
CN103555729B (zh) * 2013-10-14 2016-08-24 成都华创生物技术有限公司 一种改造的trail基因序列、表达方法及应用
CA2926183C (en) 2013-10-23 2018-07-03 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
EP3072519B1 (en) 2013-11-22 2020-08-19 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
JP6420459B2 (ja) 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
WO2016123578A1 (en) 2015-01-30 2016-08-04 The Regents Of The University Of California Protein delivery in primary hematopoietic cells
KR102636129B1 (ko) 2015-02-27 2024-02-14 주식회사 젬백스앤카엘 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
CN108348572B (zh) * 2015-03-31 2021-06-29 日东制药株式会社 含有融合组织穿透肽和抗-vegf制剂的融合蛋白的预防和治疗眼疾的药物组合物
WO2016190660A1 (ko) 2015-05-26 2016-12-01 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
KR101647804B1 (ko) * 2015-06-24 2016-08-11 한국과학기술연구원 신규 세포투과 펩타이드 및 이의 용도
EP3318265B1 (en) 2015-07-02 2021-08-18 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
WO2017127567A1 (en) * 2016-01-19 2017-07-27 Genebiologics, Llc Production of arginine-rich proteins and use as a fertilizer and germination enhancer
EP4272829A3 (en) 2016-04-07 2024-01-17 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
CN110139870B (zh) * 2016-12-16 2023-12-01 爱维斯健有限公司 细胞膜穿透肽及包含其的细胞内输送载体
KR102746901B1 (ko) 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
CA3055200A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
JP2019099578A (ja) * 2017-12-06 2019-06-24 参天製薬株式会社 細胞膜透過性ペプチドを含有する眼科用医薬組成物
KR101933217B1 (ko) 2017-12-28 2018-12-27 (주) 에빅스젠 피부 염증 억제용 펩티드 및 이를 포함하는 피부 염증 예방 또는 치료용 조성물
JP7477457B2 (ja) 2018-04-03 2024-05-01 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｃ３結合薬及びその使用方法
WO2019193204A1 (en) 2018-04-06 2019-10-10 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN109553659B (zh) * 2018-11-26 2022-06-21 上海华新生物高技术有限公司 一种细胞穿透肽及透皮干扰素
CN109575107B (zh) * 2018-11-26 2022-03-08 上海华新生物高技术有限公司 一种细胞穿透肽及可表达口服干扰素的双歧杆菌
JP6932340B2 (ja) 2019-06-21 2021-09-08 滋 天野 細胞透過性ペプチド
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
EP4210680A1 (en) 2020-09-07 2023-07-19 Cyprumed GmbH Improved pharmaceutical formulations of glp-1 receptor agonists
KR20230090333A (ko) 2020-10-16 2023-06-21 각코호우징 조쇼 가쿠엔 조성물
CN114805593A (zh) * 2021-01-19 2022-07-29 盛世泰研(广东)健康科技有限公司 一种具有穿膜功能的Penetratin-hSOD1及其制备方法与应用
KR20220157778A (ko) * 2021-05-21 2022-11-29 원큐어젠 주식회사 세포 투과성 펩타이드 및 글루카곤 유사 펩타이드-1 수용체 작용제를 포함하는 복합체
JP2025508982A (ja) 2022-03-03 2025-04-10 サイプルメド ゲーエムベーハー 治療用ペプチドおよびタンパク質の改善された経口医薬製剤
CN114984193A (zh) * 2022-06-07 2022-09-02 盛世泰研(广东)健康科技有限公司 一种psf-sod1与透明质酸的组合物及其制备方法与应用
CN115944713A (zh) * 2022-12-27 2023-04-11 中国人民解放军军事科学院军事医学研究院 一种神经营养因子和穿透肽组合物及其应用
JP7723457B2 (ja) * 2023-07-03 2025-08-14 メスキュージェナシス株式会社 細胞膜透過性を有するペプチドおよびそのスクリーニング方法
WO2026034435A1 (ja) * 2024-08-09 2026-02-12 東亞合成株式会社 ペプチドフラグメント及びその利用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123062T3 (es) 1992-08-21 1999-01-01 Biogen Inc Polipeptidos de transporte derivados de la proteina tat.
JP3770666B2 (ja) 1996-09-20 2006-04-26 株式会社ティ・ティ・エス技術研究所 経粘膜吸収製剤用組成物
AU766489B2 (en) * 1998-11-13 2003-10-16 Cyclacel Limited Transport vectors
JPWO2004037859A1 (ja) 2002-10-11 2006-02-23 株式会社三和化学研究所 Ｇｌｐ−１誘導体及びその経粘膜吸収型製剤
US7385027B2 (en) * 2003-01-07 2008-06-10 University Of Kentucky Research Foundation Membrane-permeable peptide capable of calpain inhibition
JP2005185271A (ja) * 2003-12-03 2005-07-14 Credia Japan:Kk 膜透過性ペプチド核酸
DK1814913T3 (en) * 2004-11-05 2015-09-28 Univ Leland Stanford Junior ANTIBODY-INDUCED CELL membrane damage.
CA2716565C (en) * 2008-02-28 2017-09-12 Toray Industries, Inc. Pharmaceutical composition for transnasal administration
CN102580061B (zh) * 2011-12-01 2015-04-22 武汉健宇生物医药科技有限公司 一种鼻用型胰岛素制剂及制备方法

Also Published As

Publication number Publication date
BRPI1008230B1 (pt) 2019-05-28
CA2762551C (en) 2016-11-22
WO2010134537A1 (ja) 2010-11-25
MX2011011960A (es) 2011-12-06
KR20120064650A (ko) 2012-06-19
AU2010250452B2 (en) 2014-06-05
US8772449B2 (en) 2014-07-08
BRPI1008230A2 (pt) 2016-03-08
RU2011151877A (ru) 2013-06-27
AU2010250452A1 (en) 2011-11-10
CN102428096B (zh) 2015-03-25
US20120065124A1 (en) 2012-03-15
EP2433953B1 (en) 2015-07-08
ES2546304T3 (es) 2015-09-22
EP2433953A4 (en) 2013-06-05
JPWO2010134537A1 (ja) 2012-11-12
CA2762551A1 (en) 2010-11-25
JP5653214B2 (ja) 2015-01-14
CN102428096A (zh) 2012-04-25
RU2548807C2 (ru) 2015-04-20
EP2433953A1 (en) 2012-03-28
KR101783291B1 (ko) 2017-09-29

Similar Documents

Publication Publication Date Title
PL2433953T3 (pl) Peptydy o zdolności przenikania przez błonę komórkową
GB0908613D0 (en) T Cell Reseptors
IL216624A0 (en) Fucosylation-deficient cells
GB201013639D0 (en) Cell selection
ZA201109522B (en) T cell receptors
GB0908910D0 (en) Fuel cell
EP2478584A4 (en) BATTERY
EP2448051A4 (en) FUEL CELL
GB201017421D0 (en) Cell
GB0904694D0 (en) Accumulator
EP2413405A4 (en) FUEL CELL
GB0913836D0 (en) Fuel cell
EP2441107A4 (en) THIN BATTERY
GB0920775D0 (en) Cells
ZA201108446B (en) FViII-DERIVED PEPTIDES
PT2405924E (pt) Solução eletrolítica completa adaptada ao plasma
ZA201203722B (en) Peptide
ZA201201864B (en) Fuel cell
GB0917143D0 (en) Cell stack
GB0920035D0 (en) Cell
TWI372482B (en) Battery
GB0911790D0 (en) Peptides
GB0901675D0 (en) Cells
GB0908223D0 (en) Cells
HUE052153T2 (hu) Fukoziláció-deficiens sejtek